Bharat Immunologicals & Biologicals Corporation Limited announced unaudited earnings results for the first quarter ended June 30, 2018. For the quarter, the company reported income from operations of INR 0.867 million against INR 33.468 million for the same period a year ago. Total revenue was INR 4.262 million against INR 36.135 million for the same period a year ago. Loss before finance cost and exceptional items was INR 12.423 million against INR 19.811 million for the same period a year ago. Loss from continuing operations was INR 8.265 million against INR 13.274 million for the same period a year ago. Basic and diluted loss per share was INR 0.19 against INR 0.31 for the same period a year ago.